Skip to content
Back to ISRG

Intuitive Surgical Inc

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 17, 2025
Transactions
74
Purchases
0
Sales
74
Purchase value
$0.00
Sale value
$62.51M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Gary LoebEVP & Chief Legal and Complian
4Rule 10b5-1 plan disclosed
Filed Nov 12, 2026Period of report Nov 10, 20260001561733-26-000018
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 10, 2026
Common StockF1400$458.15$183.26K6,236Direct
Filing footnotes · 1
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on January 29, 2027.
Open on SEC EDGAR
Gary S GuthartDirector
4Rule 10b5-1 plan disclosed
Filed Nov 5, 2026Period of report Nov 4, 20260001280628-26-000018
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 4, 2026
Common StockF1F210,000$457.337$4.57M1,194,530Indirectby Trust
Filing footnotes · 2
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on June 15, 2027.
  2. F2The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $453.69 to $458.27 as follows: 720 shares sold at $453.69 to $454.11; 1,845 shares sold at $455.00 to $455.15; 200 shares sold at $456.93; and 7,235 shares sold at $458.27. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Open on SEC EDGAR
Craig H BarrattDirector
4Rule 10b5-1 plan disclosed
Filed Nov 5, 2026Period of report Nov 4, 20260001277620-26-000011
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 4, 2026
Common StockF1F21,150$460.0026$529.00K0Direct
Filing footnotes · 3
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on March 15, 2027.
  2. F2The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $460.00 to $460.005 as follows: 541 shares sold at $460.00; and 609 shares sold at $460.005. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. F3Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant or at the next Shareholders Meeting, whichever should take place first, provided that vesting will cease on termination of the Directors service to the Company.
Open on SEC EDGAR
Mark BrosiusEVP & Chief Mfg and Supply Cha
4Rule 10b5-1 plan disclosed
Filed Nov 2, 2026Period of report Oct 29, 20260002010300-26-000037
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 30, 2026
Common StockF163$453.60$28.58K457Direct
SaleOct 29, 2026
Common StockF161$447.85$27.32K520Direct
Filing footnotes · 1
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.
Open on SEC EDGAR
Fredrik WidmanVP Corporate Controller
4Rule 10b5-1 plan disclosed
Filed Nov 2, 2026Period of report Oct 30, 20260001897970-26-000012
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 30, 2026
Common StockF1F25,448$436.0551$2.38M1,026Direct
Filing footnotes · 7
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on September 15, 2027.
  2. F2The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $431.64 to $453.60 as follows: 2,650 shares sold at $431.64 to $432.57; 279 shares sold at $432.71 to $433.31; 239 shares sold at $433.85 to $434.35; 79 shares sold at $434.93 to $435.64; 321 shares sold at $435.93 to $436.73; 160 shares sold at $437.33 to $437.79; 480 shares sold at $438.76 to $439.62; 120 shares sold at $439.83 to $440.03; 160 shares sold at $440.89 to $441.86; 200 shares sold at $442.20 to $442.92; 200 shares sold at $443.37 to $444.14; 160 shares sold at $444.47 to $445.32; 240 shares sold at $445.73 to $446.59; 80 shares sold at $446.86 to $447.26; and 80 shares sold at $453.60. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range
  3. F3Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. The option vests 1/8th six months after the date of grant and 1/48th monthly thereafter.
  4. F4Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. Option shall vest 7/48 one month after the date of grant and 1/48 each month thereafter.
  5. F5Non-statutory stock option granted pursuant to the 2010 Incentive Awards Plan. The option vests 1/8th six months after the date of grant and 1/48th monthly thereafter.
  6. F612.5% of the shares subject to the option vest on the six-month anniversary measured from February 10, 2023, and 1/48th of the total number of shares vest in forty-two (42) successive and equal monthly installments thereafter, subject to Reporting Person's continuous service to the Issuer through each such vesting date.
  7. F77/48th of the shares subject to the option vest on the one-month anniversary measured from August 10, 2023, and 1/48th of the total number of shares vest in forty-one (41) successive and equal monthly installments thereafter, subject to Reporting Person's continuous service to the Issuer through each such vesting date.
Open on SEC EDGAR
Mark BrosiusEVP & Chief Mfg and Supply Cha
4Rule 10b5-1 plan disclosed
Filed Oct 28, 2026Period of report Oct 26, 20260002010300-26-000035
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 28, 2026
Common StockF161$441.60$26.94K581Direct
SaleOct 27, 2026
Common StockF161$451.63$27.55K642Direct
SaleOct 26, 2026
Common StockF161$451.75$27.56K703Direct
Filing footnotes · 1
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.
Open on SEC EDGAR
Fredrik WidmanVP Corporate Controller
4Rule 10b5-1 plan disclosed
Filed Oct 26, 2026Period of report Oct 23, 20260001897970-26-000010
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 23, 2026
Common StockF1F24,047$453.2059$1.83M1,026Direct
Filing footnotes · 7
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on September 15, 2027.
  2. F2The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $444.44 to $458.02 as follows: 40 shares sold at $444.44; 120 shares sold at $445.55 to $446.44; 80 shares sold at $446.76; 120 shares sold at $448.14 to $448.37; 200 shares sold at $449.30 to $450.22; 80 shares sold at $450.34 to $451.17; 1,447 shares sold at $451.98 to $452.97; 480 shares sold at $453.01 to $453.84; 360 shares sold at $454.02 to $455.00; 400 shares sold at $455.27 to $455.78; 480 shares sold at $456.33 to $457.19; and 240 shares sold at $457.42 to $458.02. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. F3Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. The option vests 1/8th six months after the date of grant and 1/48th monthly thereafter.
  4. F4Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. Option shall vest 7/48 one month after the date of grant and 1/48 each month thereafter.
  5. F5Non-statutory stock option granted pursuant to the 2010 Incentive Awards Plan. The option vests 1/8th six months after the date of grant and 1/48th monthly thereafter.
  6. F612.5% of the shares subject to the option vest on the six-month anniversary measured from February 10, 2023, and 1/48th of the total number of shares vest in forty-two (42) successive and equal monthly installments thereafter, subject to Reporting Person's continuous service to the Issuer through each such vesting date.
  7. F77/48th of the shares subject to the option vest on the one-month anniversary measured from August 10, 2023, and 1/48th of the total number of shares vest in forty-one (41) successive and equal monthly installments thereafter, subject to Reporting Person's continuous service to the Issuer through each such vesting date.
Open on SEC EDGAR
Gary S GuthartDirector
4Rule 10b5-1 plan disclosed
Filed Oct 26, 2026Period of report Oct 23, 20260001280628-26-000016
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 23, 2026
Common StockF1F220,095$451.6117$9.08M1,204,530Indirectby Trust
Filing footnotes · 2
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on June 15, 2027.
  2. F2The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $444.04 to $458.10 as follows: 120 shares sold at $444.04 to $444.43; 240 shares sold at $445.55 to $446.21; 200 shares sold at $446.78 to $447.34; 320 shares sold at $448.00 to $448.91; 10,360 shares sold at $449.04 to $450.02; 160 shares sold at $450.13 to $450.44; 840 shares sold at $451.20 to $452.19; 3,577 shares sold at $452.20 to $453.17; 908 shares sold at $453.20 to $454.11; 702 shares sold at $454.33 to $455.32; 988 shares sold at $455.34 to $456.32; 960 shares sold at $456.36 to $457.28; and 720 shares sold at $457.36 to $458.10 The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Open on SEC EDGAR
Craig H BarrattDirector
4Rule 10b5-1 plan disclosed
Filed Oct 26, 2026Period of report Oct 23, 20260001277620-26-000009
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 23, 2026
Common StockF11,150$443.80$510.37K0Direct
Filing footnotes · 2
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on March 15, 2027.
  2. F2Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant or at the next Shareholders Meeting, whichever should take place first, provided that vesting will cease on termination of the Directors service to the Company.
Open on SEC EDGAR
Patricia L WadorsSVP Chief Human Resources Offi
4Rule 10b5-1 plan disclosed
Filed Oct 26, 2026Period of report Oct 23, 20260001274559-26-000007
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 23, 2026
Common StockF11,078$443.80$478.42K0Direct
Filing footnotes · 1
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on May 29, 2027.
Open on SEC EDGAR
Fredrik WidmanVP Corporate Controller
4Rule 10b5-1 plan disclosed
Filed Sep 16, 2026Period of report Sep 15, 20260001897970-26-000008
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 15, 2026
Common StockF1546$374.44$204.44K1,026Direct
SaleSep 15, 2026
Common StockF1543$374.44$203.32K1,026Direct
Filing footnotes · 3
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on September 15, 2027.
  2. F2Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. The option vests 1/8th six months after the date of grant and 1/48th monthly thereafter.
  3. F3Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. Option shall vest 7/48 one month after the date of grant and 1/48 each month thereafter.
Open on SEC EDGAR
Mark BrosiusEVP & Chief Mfg and Supply Cha
4Rule 10b5-1 plan disclosed
Filed Sep 11, 2026Period of report Sep 10, 20260002010300-26-000033
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 11, 2026
Common StockF125$365.79$9.14K764Direct
SaleSep 10, 2026
Common StockF123$347.66$8.00K789Direct
Filing footnotes · 1
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.
Open on SEC EDGAR
Mark BrosiusEVP & Chief Mfg and Supply Cha
4Rule 10b5-1 plan disclosed
Filed Sep 9, 2026Period of report Sep 8, 20260002010300-26-000031
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 9, 2026
Common StockF123$350.20$8.05K812Direct
SaleSep 8, 2026
Common StockF146$361.23$16.62K835Direct
Filing footnotes · 1
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.
Open on SEC EDGAR
Mark BrosiusEVP & Chief Mfg and Supply Cha
4Rule 10b5-1 plan disclosed
Filed Aug 21, 2026Period of report Aug 20, 20260002010300-26-000029
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 21, 2026
Common StockF177$375.57$28.92K881Direct
SaleAug 20, 2026
Common StockF177$396.37$30.52K958Direct
Filing footnotes · 1
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.
Open on SEC EDGAR
Mark BrosiusEVP & Chief Mfg and Supply Cha
4Rule 10b5-1 plan disclosed
Filed Aug 19, 2026Period of report Aug 17, 20260002010300-26-000027
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 19, 2026
Common StockF177$394.26$30.36K1,035Direct
SaleAug 18, 2026
Common StockF177$394.00$30.34K1,112Direct
SaleAug 17, 2026
Common StockF177$390.67$30.08K1,189Direct
Filing footnotes · 1
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.
Open on SEC EDGAR
Gary S GuthartDirector
4Rule 10b5-1 plan disclosed
Filed Aug 12, 2026Period of report Aug 11, 20260001280628-26-000014
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 11, 2026
Common StockF110,000$400.00$4.00M1,245,679Indirectby Trust
Filing footnotes · 1
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on June 15, 2027.
Open on SEC EDGAR
Amy L LaddDirector
4Rule 10b5-1 plan disclosed
Filed Aug 11, 2026Period of report Aug 10, 20260001781750-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 11, 2026
Common StockF172$393.10$28.30K179Direct
SaleAug 10, 2026
Common StockF1400$379.00$151.60K251Direct
Filing footnotes · 1
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on May 15, 2027.
Open on SEC EDGAR
Gary LoebEVP & Chief Legal and Complian
4Rule 10b5-1 plan disclosed
Filed Aug 10, 2026Period of report Aug 10, 20260001561733-26-000014
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 10, 2026
Common StockF1400$379.00$151.60K5,320Direct
Filing footnotes · 1
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on January 29, 2027.
Open on SEC EDGAR
Mark BrosiusEVP & Chief Mfg and Supply Cha
4Rule 10b5-1 plan disclosed
Filed Jul 31, 2026Period of report Jul 30, 20260002010300-26-000025
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 31, 2026
Common StockF128$351.00$9.83K1,266Direct
SaleJul 30, 2026
Common StockF128$346.83$9.71K1,294Direct
Filing footnotes · 1
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.
Open on SEC EDGAR
Mark BrosiusEVP & Chief Mfg and Supply Cha
4Rule 10b5-1 plan disclosed
Filed Jul 29, 2026Period of report Jul 27, 20260002010300-26-000023
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 29, 2026
Common StockF128$360.21$10.09K1,322Direct
SaleJul 28, 2026
Common StockF128$365.58$10.24K1,350Direct
SaleJul 27, 2026
Common StockF128$344.00$9.63K1,378Direct
Filing footnotes · 1
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.
Open on SEC EDGAR
Mark BrosiusEVP & Chief Mfg and Supply Cha
4Rule 10b5-1 plan disclosed
Filed Jun 12, 2026Period of report Jun 11, 20260002010300-26-000021
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 12, 2026
Common StockF125$414.13$10.35K1,406Direct
SaleJun 11, 2026
Common StockF123$412.16$9.48K1,431Direct
Filing footnotes · 1
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.
Open on SEC EDGAR
Mark BrosiusEVP & Chief Mfg and Supply Cha
4Rule 10b5-1 plan disclosed
Filed Jun 10, 2026Period of report Jun 8, 20260002010300-26-000019
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 10, 2026
Common StockF123$424.14$9.76K1,454Direct
SaleJun 9, 2026
Common StockF123$421.13$9.69K1,477Direct
SaleJun 8, 2026
Common StockF123$420.12$9.66K1,500Direct
Filing footnotes · 1
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.
Open on SEC EDGAR
Gary LoebEVP & Chief Legal and Complian
4Rule 10b5-1 plan disclosed
Filed Jun 10, 2026Period of report Jun 10, 20260001561733-26-000012
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 10, 2026
Common StockF1400$424.14$169.66K5,720Direct
Filing footnotes · 1
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on January 29, 2027.
Open on SEC EDGAR
Iman JeddiSVP & GM da Vinci Platforms &
4Rule 10b5-1 plan disclosed
Filed Jun 2, 2026Period of report Jun 1, 20260002106898-26-000015
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 1, 2026
Common StockF15,625$420.55$2.37M6,463Direct
Filing footnotes · 2
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on June 5, 2026.
  2. F2Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. Option shall vest 7/48 one month after the date of grant and 1/48 each month thereafter.
Open on SEC EDGAR
Mark BrosiusEVP & Chief Mfg and Supply Cha
4Rule 10b5-1 plan disclosed
Filed May 22, 2026Period of report May 21, 20260002010300-26-000017
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 22, 2026
Common StockF118$439.80$7.92K1,523Direct
SaleMay 21, 2026
Common StockF118$446.04$8.03K1,541Direct
Filing footnotes · 1
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.
Open on SEC EDGAR
Mark BrosiusEVP & Chief Mfg and Supply Cha
4Rule 10b5-1 plan disclosed
Filed May 20, 2026Period of report May 18, 20260002010300-26-000015
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 20, 2026
Common StockF118$440.38$7.93K1,559Direct
SaleMay 19, 2026
Common StockF118$440.70$7.93K1,577Direct
SaleMay 18, 2026
Common StockF118$422.47$7.60K1,595Direct
Filing footnotes · 1
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.
Open on SEC EDGAR
Gary LoebEVP & Chief Legal and Complian
4Rule 10b5-1 plan disclosed
Filed May 11, 2026Period of report May 11, 20260001561733-26-000010
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 11, 2026
Common StockF1400$446.95$178.78K6,120Direct
Filing footnotes · 1
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on January 29, 2027.
Open on SEC EDGAR
Amy L LaddDirector
4Rule 10b5-1 plan disclosed
Filed Apr 29, 2026Period of report Apr 28, 20260001781750-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 29, 2026
Common StockF1119$463.50$55.16K120Direct
SaleApr 28, 2026
Common StockF1500$473.46$236.73K239Direct
Filing footnotes · 1
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on January 29, 2027.
Open on SEC EDGAR
Myriam CuretEVP & Chief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Mar 11, 2026Period of report Mar 10, 20260001632901-26-000014
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 10, 2026
Common StockF1105$493.95$51.86K0Direct
Filing footnotes · 2
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.
  2. F212.5% of the shares subject to the option vest on the six-month anniversary measured from February 10, 2023, and 1/48th of the total number of shares vest in forty-two (42) successive and equal monthly installments thereafter, subject to Reporting Person's continuous service to the Issuer through each such vesting date.
Open on SEC EDGAR
Mark BrosiusSVP & Chief Mfg and Supply Cha
4Rule 10b5-1 plan disclosed
Filed Mar 10, 2026Period of report Mar 6, 20260002010300-26-000013
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 9, 2026
Common StockF1645$485.01$312.83K1,613Direct
SaleMar 6, 2026
Common StockF1648$490.19$317.64K2,258Direct
Filing footnotes · 1
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.
Open on SEC EDGAR
Mark BrosiusSVP & Chief Mfg and Supply Cha
4Rule 10b5-1 plan disclosed
Filed Mar 5, 2026Period of report Mar 3, 20260002010300-26-000011
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 5, 2026
Common StockF1648$495.20$320.89K2,906Direct
SaleMar 4, 2026
Common StockF1F32,362$498.6804$1.18M3,554Direct
SaleMar 3, 2026
Common StockF1F2648$488.10$316.29K5,916Direct
Filing footnotes · 3
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.
  2. F2The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $487.18 to $489.94 as follows: 432 shares sold at $487.18 and 216 shares sold at $489.94. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. F3The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $495.19 to $500.00 as follows: 648 shares sold at $495.19 and 1,714 shares sold at $500.00. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Open on SEC EDGAR
Fredrik WidmanVP Corporate Controller
4Rule 10b5-1 plan disclosed
Filed Mar 3, 2026Period of report Feb 27, 20260001897970-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 3, 2026
Common StockF1118$487.18$57.49K1,026Direct
SaleFeb 27, 2026
Common StockF1249$499.71$124.43K909Direct
Filing footnotes · 3
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on May 21, 2026.
  2. F2RSUs vest 25% per year over a four year period, commencing on the first anniversary of the grant date. RSUs convert into common stock on the vest date on a one-for-one basis. 25% of the shares have been released and a portion of the shares were held back to cover the statutory tax withholding requirements. The net shares were deposited into the holders account.
  3. F3Each RSU granted represents a contingent right to receive one share of Intuitive Surgical common stock. The grant vests 25% on the first anniversary of the date of grant and annually thereafter, over a four year period.
Open on SEC EDGAR
Myriam CuretEVP & Chief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Mar 3, 2026Period of report Mar 2, 20260001632901-26-000012
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 3, 2026
Common StockF14,728$487.18$2.30M409Indirectby Trust
SaleMar 2, 2026
Common StockF1125$492.59$61.57K5,137Indirectby Trust
Filing footnotes · 2
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.
  2. F2Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. Option shall vest 7/48 one month after the date of grant and 1/48 each month thereafter.
Open on SEC EDGAR
Myriam CuretEVP & Chief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Mar 2, 2026Period of report Feb 27, 20260001632901-26-000010
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 27, 2026
Common StockF12,345$499.71$1.17M409Indirectby Trust
Filing footnotes · 5
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.
  2. F2RSUs vest 25% per year over a four year period, commencing on the first anniversary of the grant date. RSUs convert into common stock on the vest date on a one-for-one basis. 25% of the shares have been released and a portion of the shares were held back to cover the statutory tax withholding requirements. The net shares were deposited into the holders account.
  3. F3Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.
  4. F4This transaction represents the withholding of shares to cover taxes applicable to a settlement of PSUs reported on this Form 4.
  5. F5Each RSU granted represents a contingent right to receive one share of Intuitive Surgical common stock. The grant vests 25% on the first anniversary of the date of grant and annually thereafter, over a four year period.
Open on SEC EDGAR
Patricia L WadorsSVP Chief Human Resources Offi
4Rule 10b5-1 plan disclosed
Filed Feb 27, 2026Period of report Feb 26, 20260001274559-26-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 27, 2026
Common StockF2220$499.71$109.94K0Direct
Filing footnotes · 3
  1. F1RSUs vest 25% per year over a four year period, commencing on the first anniversary of the grant date. RSUs convert into common stock on the vest date on a one-for-one basis. 25% of the shares have been released and a portion of the shares were held back to cover the statutory tax withholding requirements. The net shares were deposited into the holders account.
  2. F2The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on June 5, 2026.
  3. F3Each RSU granted represents a contingent right to receive one share of Intuitive Surgical common stock. The grant vests 25% on the first anniversary of the date of grant and annually thereafter, over a four year period.
Open on SEC EDGAR
Fredrik WidmanVP Corporate Controller
4Rule 10b5-1 plan disclosed
Filed Feb 11, 2026Period of report Feb 10, 20260001897970-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 11, 2026
Common StockF2133$494.96$65.83K660Direct
Filing footnotes · 3
  1. F1RSUs vest 25% per year over a four year period, commencing on each anniversary of February 10, 2023. RSUs convert into common stock on the vest date on a one-for-one basis. 25% of the shares have been released and a portion of the shares were held back to cover the statutory tax withholding requirements. The net shares were deposited into the holders account.
  2. F2The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on May 21, 2026.
  3. F3Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock upon vesting. 25% of the RSUs shall vest on each anniversary of February 10, 2023, subject to Reporting Person's continuous service to the Issuer through each such vesting date.
Open on SEC EDGAR
Myriam CuretEVP & Chief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Feb 11, 2026Period of report Feb 10, 20260001632901-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 11, 2026
Common StockF2421$494.96$208.38K409Indirectby Trust
SaleFeb 10, 2026
Common StockF2105$494.65$51.94K830Indirectby Trust
Filing footnotes · 4
  1. F1RSUs vest 25% per year over a four year period, commencing on each anniversary of February 10, 2023. RSUs convert into common stock on the vest date on a one-for-one basis. 25% of the shares have been released and a portion of the shares were held back to cover the statutory tax withholding requirements. The net shares were deposited into the holders account.
  2. F2The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.
  3. F312.5% of the shares subject to the option vest on the six-month anniversary measured from February 10, 2023, and 1/48th of the total number of shares vest in forty-two (42) successive and equal monthly installments thereafter, subject to Reporting Person's continuous service to the Issuer through each such vesting date.
  4. F4Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock upon vesting. 25% of the RSUs shall vest on each anniversary of February 10, 2023, subject to Reporting Person's continuous service to the Issuer through each such vesting date.
Open on SEC EDGAR
Myriam CuretEVP & Chief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Jan 30, 2026Period of report Jan 28, 20260001632901-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 29, 2026
Common StockF1126$520.02$65.52K0Direct
Filing footnotes · 3
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.
  2. F2Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. Option shall vest 7/48 one month after the date of grant and 1/48 each month thereafter.
  3. F3Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date.
Open on SEC EDGAR
Myriam CuretEVP & Chief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Jan 28, 2026Period of report Jan 27, 20260001632901-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 27, 2026
Common StockF1105$532.61$55.92K0Direct
SaleJan 27, 2026
Common StockF1125$532.61$66.58K0Direct
Filing footnotes · 3
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.
  2. F2Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. Option shall vest 7/48 one month after the date of grant and 1/48 each month thereafter.
  3. F312.5% of the shares subject to the option vest on the six-month anniversary measured from February 10, 2023, and 1/48th of the total number of shares vest in forty-two (42) successive and equal monthly installments thereafter, subject to Reporting Person's continuous service to the Issuer through each such vesting date.
Open on SEC EDGAR
Gary S GuthartDirector
4Rule 10b5-1 plan disclosed
Filed Jan 28, 2026Period of report Jan 27, 20260001280628-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 27, 2026
Common StockF1F224,500$530.0981$12.99M3,694Direct
SaleJan 27, 2026
Common StockF1F31,400$531.5285$744.14K15,720IndirectTrust FBO Daughter
SaleJan 27, 2026
Common StockF1F41,400$531.5208$744.13K15,720IndirectTrust FBO Son
Filing footnotes · 5
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026.
  2. F2The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $525.51 to $534.00 as follows: 2,500 shares sold at $525.51 to $525.71; 280 shares sold at $526.94 to $527.41; 2,252 shares sold at $528.23 to $529.18; 9,860 shares sold at $529.27 to $530.27; 3,475 shares sold at $530.29 to $531.22; 1,589 shares sold at $531.37 to $532.24; 3,704 shares sold at $532.53 to $533.41; and 840 shares sold at $533.82 to $534.00. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. F3The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $529.77 to $534.00 as follows: 520 shares sold at $529.77 to $530.61; 298 shares sold at $530.98 to $531.87; 302 shares sold at $532.05 to $532.61; and 280 shares sold at $533.82 to $534.00. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  4. F4The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $529.77 to $534.00 as follows: 520 shares sold at $529.77 to $530.61; 360 shares sold at $530.98 to $531.86; 240 shares sold at $532.05 to $532.61; and 280 shares sold at $533.82 to $534.00. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  5. F5Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. Option shall vest 7/48 one month after the date of grant and 1/48 each month thereafter.
Open on SEC EDGAR
Mark BrosiusSee Remarks
4Rule 10b5-1 plan disclosed
Filed Dec 17, 2025Period of report Dec 15, 20250001610717-25-000419
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 15, 2025
Common StockF1464$548.49$254.50K131Direct
Filing footnotes · 1
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.
Open on SEC EDGAR
Mark BrosiusSee Remarks
4/ARule 10b5-1 plan disclosedAmendment
Filed Dec 17, 2025Period of report Dec 12, 20250001610717-25-000418
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 12, 2025
Common StockF2F1312$547.36$170.78K595Direct
Filing footnotes · 2
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.
  2. F2The third transaction line in Table I of the Form 4 filed by the Reporting Person on 12/15/2025 incorrectly reported the transaction details. The transaction line as reported herein has been restated to correct the errors in the original Form 4. Except as otherwise noted in this footnote, all other information disclosed in the Reporting Person's original Form 4 was accurately reported.
Open on SEC EDGAR
Myriam CuretEVP & Chief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Dec 10, 2025Period of report Dec 10, 20250001632901-25-000010
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 10, 2025
Common StockF1104$559.90$58.23K0Direct
Filing footnotes · 2
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.
  2. F212.5% of the shares subject to the option vest on the six-month anniversary measured from February 10, 2023, and 1/48th of the total number of shares vest in forty-two (42) successive and equal monthly installments thereafter, subject to Reporting Person's continuous service to the Issuer through each such vesting date.
Open on SEC EDGAR
Myriam CuretEVP & Chief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Dec 2, 2025Period of report Dec 1, 20250001632901-25-000008
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 1, 2025
Common StockF1125$568.99$71.12K0Direct
Filing footnotes · 2
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026.
  2. F2Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. Option shall vest 7/48 one month after the date of grant and 1/48 each month thereafter.
Open on SEC EDGAR
Gary S GuthartDirector · Executive Chair of the Board o
4Rule 10b5-1 plan disclosed
Filed Dec 2, 2025Period of report Dec 1, 20250001280628-25-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 1, 2025
Common StockF1F222,806$570.8902$13.02M2,694Direct
Filing footnotes · 3
  1. F1The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026.
  2. F2The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $568.62 to $573.54 as follows: 5,550 shares sold at $568.62 to $569.62; 6,304 shares sold at $569.64 to $570.63; 2,285 shares sold at $570.66 to $571.61; 5,528 shares sold at $571.70 to $572.70; 3,139 shares sold at $572.72 to $573.54. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. F3Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. The option vests 1/8th six months after the date of grant and 1/48th monthly thereafter.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.